Jammu Journal

Acute Ischemic Stroke Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Tasly Pharmaceutical, AstraZeneca, Guangzhou Recomgen Biotech, Supergene, Healios, Abbvie and Other

 Breaking News
  • No posts were found

Acute Ischemic Stroke Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Tasly Pharmaceutical, AstraZeneca, Guangzhou Recomgen Biotech, Supergene, Healios, Abbvie and Other

May 14
20:50 2021
Acute Ischemic Stroke Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Tasly Pharmaceutical, AstraZeneca, Guangzhou Recomgen Biotech, Supergene, Healios, Abbvie and Other

Acute Ischemic Stroke Pipeline

Acute Ischemic stroke results from a sudden cessation of adequate amounts of blood reaching parts of the brain. Ischemic strokes can be divided according to territory affected or mechanism. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.

DelveInsight’s, “Acute Ischemic Stroke Pipeline Insight, 2021” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Some of Acute Ischemic Stroke Companies are:

  • Tasly Pharmaceutical
  • AstraZeneca
  • Guangzhou Recomgen Biotech
  • Supergene
  • Healios
  • Abbvie
  • DiaMedica Therapeutics
  • Jeil Pharmaceutical
  • Lumosa Therapeutics
  • Pharmazz
  • Teijin Pharma Limited
  • Acticor Biotech
  • aptaTargets
  • Meridigen Biotech
  • DiaMedica therapeutics
  • NoNO Inc
  • Daiichi Sankyo Company
  • Genentech
  • Shin Poong Pharmaceutical
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight

 

DelveInsight’s Acute Ischemic Stroke report covers around 20+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Acute Ischemic Stroke Therapies are:

  • Recombinant human urokinase
  • Ticagrelor
  • SP-8203
  • rhTNK-tPA/rt-PA
  • tenecteplase
  • Recombinant staphylokinase
  • HLCM051
  • DS 1040
  • Elezanumab
  • Recombinant human tissue kallikrein
  • JPI-289
  • LT3001
  • JTR-161
  • ACT017
  • ApTOLL
  • UMC119-06
  • DMI 199
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight

 

Current Acute Ischemic Stroke Treatment Scenario and Acute Ischemic Stroke Emerging Therapies:

  • How many companies are developing Acute Ischemic Stroke drugs?
  • How many Acute Ischemic Stroke drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Ischemic Stroke and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Acute Ischemic Stroke: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Acute Ischemic Stroke – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Acute Ischemic Stroke Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Nerinetide: NoNO

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

SP-8203: Shin Poong Pharmaceutical

Drug profiles in the detailed report…..

Early stage products (Phase I/II)

• Comparative Analysis

JTR 161: Teijin Pharma Limited

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Acute Ischemic Stroke Key Companies

Acute Ischemic Stroke Key Products

Acute Ischemic Stroke- Unmet Needs

Acute Ischemic Stroke- Market Drivers and Barriers

Acute Ischemic Stroke- Future Perspectives and Conclusion

Acute Ischemic Stroke Analyst Views

Acute Ischemic Stroke Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight